CD4 T cells in immunity and immunotherapy of Alzheimer's disease

Immunology

Volumn 139, Issue 4, 2013, Pages 438-446

  Monsonego, Alon ^a   Nemirovsky, Anna ^a   Harpaz, Idan ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

A antibodies; Alzheimer's disease; Amyloid protein (A ); CD4 T cells; Immunotherapy

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; BRAIN PEPTIDE; EPITOPE; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; QS 21;

ADAPTIVE IMMUNITY; ALLELE; ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; ANTIGEN PRESENTATION; AUTOIMMUNITY; BRAIN BLOOD VESSEL; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELL MIGRATION; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); ENCEPHALITIS; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; MICROGLIA; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; VACCINATION;

AΒ ANTIBODIES; ALZHEIMER'S DISEASE; AMYLOID Β-PROTEIN (AΒ); CD4 T CELLS; IMMUNOTHERAPY;

ADAPTIVE IMMUNITY; ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PEPTIDES; ANIMALS; AUTOIMMUNITY; CD4-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOTHERAPY;

EID: 84879819519     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12103     Document Type: Review

References (118)

1. Rosenmann H, Grigoriadis N, Eldar-Levy H et al. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. Exp Neurol 2008; 212:71-84.
2. Selkoe DJ. Presenilin, Notch, and the genesis and treatment of Alzheimer's disease. Proc Natl Acad Sci USA 2001; 98:11039-41.
3. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol 2007; 8:101-12.
4. Walsh DM, Selkoe DJ. A β oligomers - a decade of discovery. J Neurochem 2007; 101:1172-84.
5. Citron M, Westaway D, Xia W et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nat Med 1997; 3:67-72.
6. Moehlmann T, Winkler E, Xia X et al. Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Aβ 42 production. Proc Natl Acad Sci USA 2002; 99:8025-30.
7. Heneka MT, Kummer MP, Stutz A et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 2013; 493:674-8.
8. McGeer EG, Klegeris A, McGeer PL. Inflammation, the complement system and the diseases of aging. Neurobiol Aging 2005; 26(Suppl. 1):94-7.
9. Vom Berg J, Prokop S, Miller KR et al. Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat Med 2012; 18:1812-9.
10. Shankar GM, Li S, Mehta TH et al. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008; 14:837-42.
11. Herzig MC, Winkler DT, Burgermeister P et al. Aβ is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci 2004; 7:954-60.
12. Meyer EP, Ulmann-Schuler A, Staufenbiel M, Krucker T. Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease. Proc Natl Acad Sci USA 2008; 105:3587-92.
13. Thal DR, Griffin WS, de Vos RA, Ghebremedhin E. Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. Acta Neuropathol 2008; 115:599-609.
14. Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc Natl Acad Sci USA 1997; 94:4109-12.
15. Solomon B, Koppel R, Hanan E, Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide. Proc Natl Acad Sci USA 1996; 93:452-5.
16. Schenk D, Barbour R, Dunn W et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400:173-7.
17. Lemere CA, Maron R, Spooner ET et al. Nasal A β treatment induces anti-A β antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann N Y Acad Sci 2000; 920:328-31.
18. Weiner HL, Lemere CA, Maron R et al. Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 2000; 48:567-79.
19. Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE. Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging 2001; 22:721-7.
20. Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, Wisniewski T. Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 2001; 159:439-47.
21. Mucke L, Masliah E, Yu GQ et al. High-level neuronal expression of aβ 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 2000; 20:4050-8.
22. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 2003; 9:448-52.
23. Orgogozo JM, Gilman S, Dartigues JF et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 2003; 61:46-54.
24. Schenk D. Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 2002; 3:824-8.
25. Gilman S, Koller M, Black RS et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64:1553-62.
26. Monsonego A, Zota V, Karni A et al. Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease. J Clin Invest 2003; 112:415-22.
27. Zota V, Nemirovsky A, Baron R, Fisher Y, Selkoe DJ, Altmann DM, Weiner HL, Monsonego A. HLA-DR alleles in amyloid β-peptide autoimmunity: a highly immunogenic role for the DRB1*1501 allele. J Immunol 2009; 183:3522-30.
28. Hock C, Konietzko U, Papassotiropoulos A et al. Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease. Nat Med 2002; 8:1270-5.
29. Holmes C, Boche D, Wilkinson D et al. Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372:216-23.
30. Monsonego A, Imitola J, Petrovic S et al. Aβ-induced meningoencephalitis is IFN-γ-dependent and is associated with T cell-dependent clearance of Aβ in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2006; 103:5048-53.
31. + T cell responses to amyloid-β peptide in mice through regulatory T cell-mediated inhibition. J Immunol 2011; 187:4492-500.
32. Das P, Chapoval S, Howard V, David CS, Golde TE. Immune responses against Aβ1-42 in HLA class II transgenic mice: implications for Aβ1-42 immune-mediated therapies. Neurobiol Aging 2003; 24:969-76.
33. Lemere CA, Maron R, Selkoe DJ, Weiner HL. Nasal vaccination with β-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol 2001; 20:705-11.
34. Monsonego A, Maron R, Zota V, Selkoe DJ, Weiner HL. Immune hyporesponsiveness to amyloid β-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl Acad Sci USA 2001; 98:10273-8.
35. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-β immunotherapy? Nat Rev Neurol 2010; 6:108-19.
36. Bard F, Barbour R, Cannon C et al. Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 2003; 100:2023-8.
37. Ghochikyan A, Mkrtichyan M, Petrushina I, Movsesyan N, Karapetyan A, Cribbs DH, Agadjanyan MG. Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Aβ antibody response with Alum to Quil A adjuvant switch. Vaccine 2006; 24:2275-82.
38. Zurbriggen R, Amacker M, Kammer AR, Westerfeld N, Borghgraef P, Van Leuven F, Van der Auwera I, Wera S. Virosome-based active immunization targets soluble amyloid species rather than plaques in a transgenic mouse model of Alzheimer's disease. J Mol Neurosci 2005; 27:157-66.
39. Muhs A, Hickman DT, Pihlgren M et al. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci USA 2007; 104:9810-15.
40. Okura Y, Miyakoshi A, Kohyama K, Park IK, Staufenbiel M, Matsumoto Y. Nonviral Aβ DNA vaccine therapy against Alzheimer's disease: long-term effects and safety. Proc Natl Acad Sci USA 2006; 103:9619-24.
41. Movsesyan N, Ghochikyan A, Mkrtichyan M et al. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS ONE 2008; 3:e2124.
42. Tabira T. Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies. Tohoku J Exp Med 2010; 220:95-106.
43. Amir-Kroll H, Nussbaum G, Cohen IR. Proteins and their derived peptides as carriers in a conjugate vaccine for Streptococcus pneumoniae: self-heat shock protein 60 and tetanus toxoid. J Immunol 2003; 170:6165-71.
44. Nemirovsky A, Fisher Y, Baron R, Cohen IR, Monsonego A. Amyloid β-HSP60 peptide conjugate vaccine treats a mouse model of Alzheimer's disease. Vaccine 2011; 29:4043-50.
45. Konen-Waisman S, Cohen A, Fridkin M, Cohen IR. Self heat-shock protein (hsp60) peptide serves in a conjugate vaccine against a lethal pneumococcal infection. J Infect Dis 1999; 179:403-13.
46. Quintana FJ, Cohen IR. HSP60 speaks to the immune system in many voices. Novartis Found Symp 2008; 291:101-111; discussion 11-4, 37-40.
47. Cohen N, Stolarsky-Bennun M, Amir-Kroll H et al. Pneumococcal capsular polysaccharide is immunogenic when present on the surface of macrophages and dendritic cells: TLR4 signaling induced by a conjugate vaccine or by lipopolysaccharide is conducive. J Immunol 2008; 180:2409-18.
48. Nemirovsky A, Shapiro J, Baron R, Kompaniets A, Monsonego A. Active Aβ vaccination fails to enhance amyloid clearance in a mouse model of Alzheimer's disease with Aβ42-driven pathology. J Neuroimmunol 2012; 247:95-9.
49. Wang A, Das P, Switzer RC 3rd, Golde TE, Jankowsky JL. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-β immunotherapy. J Neurosci 2011; 31:4124-36.
50. Adolfsson O, Pihlgren M, Toni N et al. An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci 2012; 32:9677-89.
51. Edri-Brami M, Rosental B, Hayoun D et al. Glycans in sera of amyotrophic lateral sclerosis patients and their role in killing neuronal cells. PLoS ONE 2012; 7:e35772.
52. Lunnon K, Teeling JL, Tutt AL, Cragg MS, Glennie MJ, Perry VH. Systemic inflammation modulates Fc receptor expression on microglia during chronic neurodegeneration. J Immunol 2011; 186:7215-24.
53. Baron R, Nemirovsky A, Harpaz I, Cohen H, Owens T, Monsonego A. IFN-γ enhances neurogenesis in wild-type mice and in a mouse model of Alzheimer's disease. FASEB J 2008; 22:2843-52.
54. Butovsky O, Ziv Y, Schwartz A, Landa G, Talpalar AE, Pluchino S, Martino G, Schwartz M. Microglia activated by IL-4 or IFN-γ differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells. Mol Cell Neurosci 2006; 31:149-160.
55. + T cells following ischemic stroke. J Neurol Sci 2005; 233:125-32.
56. Buckwalter MS, Coleman BS, Buttini M, Barbour R, Schenk D, Games D, Seubert P, Wyss-Coray T. Increased T cell recruitment to the CNS after amyloid β 1-42 immunization in Alzheimer's mice overproducing transforming growth factor-β 1. J Neurosci 2006; 26:11437-41.
57. Shaftel SS, Carlson TJ, Olschowka JA, Kyrkanides S, Matousek SB, O'Banion MK. Chronic interleukin-1β expression in mouse brain leads to leukocyte infiltration and neutrophil-independent blood-brain barrier permeability without overt neurodegeneration. J Neurosci 2007; 27:9301-9.
58. Hauben E, Butovsky O, Nevo U et al. Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J Neurosci 2000; 20:6421-30.
59. Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 1999; 5:49-55.
60. Holmoy T. T cells in amyotrophic lateral sclerosis. Eur J Neurol 2008; 15:360-6.
61. + T cells. J Immunol 2003; 171:6549-55.
62. Fisher Y, Nemirovsky A, Baron R, Monsonego A. T cells specifically targeted to amyloid plaques enhance plaque clearance in a mouse model of Alzheimer's disease. PLoS ONE 2010; 5:e10830.
63. Butovsky O, Koronyo-Hamaoui M, Kunis G, Ophir E, Landa G, Cohen H, Schwartz M. Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc Natl Acad Sci USA 2006; 103:11784-9.
64. Aharoni R, Arnon R, Eilam R. Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. J Neurosci 2005; 25:8217-28.
65. Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. Neurol Sci 2006; 27(Suppl. 1):S1-S7.
66. Shaked I, Tchoresh D, Gersner R, Meiri G, Mordechai S, Xiao X, Hart RP, Schwartz M. Protective autoimmunity: interferon-γ enables microglia to remove glutamate without evoking inflammatory mediators. J Neurochem 2005; 92:997-1009.
67. Wolf SA, Steiner B, Akpinarli A, Kammertoens T, Nassenstein C, Braun A, Blankenstein T, Kempermann G. CD4-positive T lymphocytes provide a neuroimmunological link in the control of adult hippocampal neurogenesis. J Immunol 2009; 182:3979-84.
68. Mastrangelo MA, Sudol KL, Narrow WC, Bowers WJ. Interferon-γ differentially affects Alzheimer's disease pathologies and induces neurogenesis in triple transgenic-AD mice. Am J Pathol 2009; 175:2076-88.
69. Gaikwad S, Larionov S, Wang Y, Dannenberg H, Matozaki T, Monsonego A, Thal DR, Neumann H. Signal regulatory protein-β1: a microglial modulator of phagocytosis in Alzheimer's disease. Am J Pathol 2009; 175:2528-39.
70. Takahashi K, Rochford CD, Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med 2005; 201:647-57.
71. Tran EH, Prince EN, Owens T. IFN-γ shapes immune invasion of the central nervous system via regulation of chemokines. J Immunol 2000; 164:2759-68.
72. Lees JR, Golumbek PT, Sim J, Dorsey D, Russell JH. Regional CNS responses to IFN-γ determine lesion localization patterns during EAE pathogenesis. J Exp Med 2008; 205:2633-42.
73. Pierson E, Simmons SB, Castelli L, Goverman JM. Mechanisms regulating regional localization of inflammation during CNS autoimmunity. Immunol Rev 2012; 248:205-15.
74. Balabanov R, Strand K, Goswami R, McMahon E, Begolka W, Miller SD, Popko B. Interferon-γ-oligodendrocyte interactions in the regulation of experimental autoimmune encephalomyelitis. J Neurosci 2007; 27:2013-24.
75. Kwidzinski E, Bunse J, Aktas O, Richter D, Mutlu L, Zipp F, Nitsch R, Bechmann I. Indolamine 2, 3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J 2005; 19:1347-9.
76. Wheeler RD, Zehntner SP, Kelly LM, Bourbonniere L, Owens T. Elevated interferon γ expression in the central nervous system of tumour necrosis factor receptor 1-deficient mice with experimental autoimmune encephalomyelitis. Immunology 2006; 118:527-38.
77. Butovsky O, Bukshpan S, Kunis G, Jung S, Schwartz M. Microglia can be induced by IFN-γ or IL-4 to express neural or dendritic-like markers. Mol Cell Neurosci 2007; 35:490-500.
78. Gao X, Gillig TA, Ye P, D'Ercole AJ, Matsushima GK, Popko B. Interferon-γ protects against cuprizone-induced demyelination. Mol Cell Neurosci 2000; 16:338-49.
79. Kim SJ, Son TG, Kim K, Park HR, Mattson MP, Lee J. Interferon-γ promotes differentiation of neural progenitor cells via the JNK pathway. Neurochem Res 2007; 32:1399-1406.
80. Lee J, Kim SJ, Son TG, Chan SL, Mattson MP. Interferon-γ is up-regulated in the hippocampus in response to intermittent fasting and protects hippocampal neurons against excitotoxicity. J Neurosci Res 2006; 83:1552-7.
81. Song JH, Wang CX, Song DK, Wang P, Shuaib A, Hao C. Interferon γ induces neurite outgrowth by up-regulation of p35 neuron-specific cyclin-dependent kinase 5 activator via activation of ERK1/2 pathway. J Biol Chem 2005; 280:12896-901.
82. Wong G, Goldshmit Y, Turnley AM. Interferon-γ but not TNF α promotes neuronal differentiation and neurite outgrowth of murine adult neural stem cells. Exp Neurol 2004; 187:171-7.
83. Corbin JG, Kelly D, Rath EM, Baerwald KD, Suzuki K, Popko B. Targeted CNS expression of interferon-γ in transgenic mice leads to hypomyelination, reactive gliosis, and abnormal cerebellar development. Mol Cell Neurosci 1996; 7:354-70.
84. Renno T, Taupin V, Bourbonniere L et al. Interferon-γ in progression to chronic demyelination and neurological deficit following acute EAE. Mol Cell Neurosci 1998; 12:376-89.
85. Fisher Y, Nemirovsky A, Baron R, Monsonego A. Dendritic cells regulate amyloid-β-specific T-cell entry into the brain: the role of perivascular amyloid-β. J Alzheimers Dis 2011; 27:99-111.
86. Boche D, Zotova E, Weller RO et al. Consequence of Aβ immunization on the vasculature of human Alzheimer's disease brain. Brain 2008; 131:3299-310.
87. Carare RO, Bernardes-Silva M, Newman TA et al. Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol Appl Neurobiol 2008; 34:131-44.
88. Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. Perivascular drainage of amyloid-β peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 2008; 18:253-66.
89. Serafini B, Columba-Cabezas S, Di Rosa F, Aloisi F. Intracerebral recruitment and maturation of dendritic cells in the onset and progression of experimental autoimmune encephalomyelitis. Am J Pathol 2000; 157:1991-2002.
90. Archambault AS, Sim J, Gimenez MA, Russell JH. Defining antigen-dependent stages of T cell migration from the blood to the central nervous system parenchyma. Eur J Immunol 2005; 35:1076-85.
91. Greter M, Heppner FL, Lemos MP, Odermatt BM, Goebels N, Laufer T, Noelle RJ, Becher B. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 2005; 11:328-34.
92. Bartholomaus I, Kawakami N, Odoardi F et al. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 2009; 462:94-8.
93. Engelhardt B, Ransohoff RM. Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol 2012; 33:579-89.
94. Ransohoff RM, Kivisakk P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 2003; 3:569-81.
95. de Rosbo NK, Ben-Nun A. T-cell responses to myelin antigens in multiple sclerosis; relevance of the predominant autoimmune reactivity to myelin oligodendrocyte glycoprotein. J Autoimmun 1998; 11:287-99.
96. Waldner H, Whitters MJ, Sobel RA, Collins M, Kuchroo VK. Fulminant spontaneous autoimmunity of the central nervous system in mice transgenic for the myelin proteolipid protein-specific T cell receptor. Proc Natl Acad Sci USA 2000; 97:3412-7.
97. Ercolini AM, Miller SD. Mechanisms of immunopathology in murine models of central nervous system demyelinating disease. J Immunol 2006; 176:3293-8.
98. Krishnamoorthy G, Saxena A, Mars LT et al. Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis. Nat Med 2009; 15:626-32.
99. H17 cells. Nat Med 2008; 14:337-42.
100. Pfeifer LA, White LR, Ross GW, Petrovitch H, Launer LJ. Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology 2002; 58:1629-34.
101. Burbach GJ, Vlachos A, Ghebremedhin E, Del Turco D, Coomaraswamy J, Staufenbiel M, Jucker M, Deller T. Vessel ultrastructure in APP23 transgenic mice after passive anti-Aβ immunotherapy and subsequent intracerebral hemorrhage. Neurobiol Aging 2007; 28:202-12.
102. Racke MM, Boone LI, Hepburn DL et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid β. J Neurosci 2005; 25:629-36.
103. Maue AC, Yager EJ, Swain SL, Woodland DL, Blackman MA, Haynes L. T-cell immunosenescence: lessons learned from mouse models of aging. Trends Immunol 2009; 30:301-5.
104. Panda A, Arjona A, Sapey E, Bai F, Fikrig E, Montgomery RR, Lord JM, Shaw AC. Human innate immunosenescence: causes and consequences for immunity in old age. Trends Immunol 2009; 30:325-33.
105. Akiyama H, Barger S, Barnum S et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21:383-421.
106. Rocha NP, Teixeira AL, Coelho FM et al. Peripheral blood mono-nuclear cells derived from Alzheimer's disease patients show elevated baseline levels of secreted cytokines but resist stimulation with β-amyloid peptide. Mol Cell Neurosci 2012; 49:77-84.
107. Njie EG, Boelen E, Stassen FR, Steinbusch HW, Borchelt DR, Streit WJ. Ex vivo cultures of microglia from young and aged rodent brain reveal age-related changes in microglial function. Neurobiol Aging 2012; 33:195 e1-12.
108. Streit WJ, Sammons NW, Kuhns AJ, Sparks DL. Dystrophic microglia in the aging human brain. Glia 2004; 45:208-12.
109. Tremblay ME, Zettel ML, Ison JR, Allen PD, Majewska AK. Effects of aging and sensory loss on glial cells in mouse visual and auditory cortices. Glia 2012; 60:541-58.
110. Villeda SA. The circulatory systemic environment as a modulator of neurogenesis and brain aging Autoimmun Rev 2012; doi: 10.1016/j.autrev.2012.10.014.
111. Lucin KM, Wyss-Coray T. Immune activation in brain aging and neurodegeneration: too much or too little? Neuron 2009; 64:110-22.
112. Mirochnic S, Wolf S, Staufenbiel M, Kempermann G. Age effects on the regulation of adult hippocampal neurogenesis by physical activity and environmental enrichment in the APP23 mouse model of Alzheimer disease. Hippocampus 2009; 19:1008-18.
113. Kutzler MA, Cao C, Bai Y et al. Mapping of immune responses following wild-type and mutant AΒ42 plasmid or peptide vaccination in different mouse haplotypes and HLA Class II transgenic mice. Vaccine 2006; 24:4630-9.
114. Wilkinson K, El Khoury J. Microglial scavenger receptors and their roles in the pathogenesis of Alzheimer's disease. Int J Alzheimers Dis 2012; 2012:489456.
115. Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, Heneka MT. PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J Neurosci 2012; 32:17321-31.
116. Prodinger C, Bunse J, Kruger M et al. CD11c-expressing cells reside in the juxtavascular parenchyma and extend processes into the glia limitans of the mouse nervous system. Acta Neuropathol 2011; 121:445-58.
117. Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol 2012; 12:623-35.
118. Shechter R, London A, Schwartz M. Orchestrated leukocyte recruitment to immune-privileged sites: absolute barriers versus educational gates. Nat Rev Immunol 2013; 13:206-18.